In a subgroup analysis of the TRIBE study, patients with metastatic colorectal cancer with the BRAF mutation were treated with FOLFOXIRI + bevacizumab (n = 16) and FOLFIRI + bevacizumab (n = 12). The gene discussed is BRAF; the disease is metastatic colorectal cancer.